On August 28, 2022 Atomwise, an artificial intelligence–based drug discovery firm, reported that it has formed a research pact with Sanofi in which the partners will use Atomwise’s AtomNet computational platform on up to five drug targets (Press release, Atomwise, AUG 28, 2022, View Source [SID1234618859]). Sanofi will pay Atomwise $20 million, plus possible milestones, to identify, synthesize, and advance small molecules that will be exclusive to Sanofi. Atomwise’s platform employs AI algorithms for structure-based drug design and to search its virtual library of more than 3 trillion compounds that can be synthesized.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!